ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

ALZN Alzamend Neuro Inc

0,400501
0,0015 (0,38%)
Zuletzt aktualisiert: 18:53:51
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Alzamend Neuro Inc ALZN NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,0015 0,38% 0,400501 18:53:51
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,4189 0,398 0,4299 0,399
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
11.6.202422:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
03.6.202422:30EDGAR2Form S-1 - General form for registration of securities under..
31.5.202422:59EDGAR2Form DEF 14A - Other definitive proxy statements
22.5.202422:30EDGAR2Form 8-K - Current report
22.5.202414:00BWAlzamend Neuro Announces Favorable Decision from Nasdaq..
16.5.202422:30EDGAR2Form 5 - Annual statement of changes in beneficial ownership..
14.5.202414:00BWAlzamend Neuro Announces Initial Closing of Private..
13.5.202422:30EDGAR2Form 8-K - Current report
10.5.202423:06EDGAR2Form PRE 14A - Other preliminary proxy statements
10.5.202422:30EDGAR2Form 8-K/A - Current report: [Amend]
10.5.202412:30EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
09.5.202422:30EDGAR2Form 8-K - Current report
09.5.202422:20EDGAR2Form 8-K - Current report
09.5.202414:00BWAlzamend Neuro Announces Agreement for Registered Direct..
07.5.202422:31EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
07.5.202422:30EDGAR2Form 8-K - Current report
07.5.202414:00BWAlzamend Neuro Announces Termination of At-the-Market Equity..
07.3.202422:30EDGAR2Form 8-K - Current report
02.2.202422:30EDGAR2Form 8-K - Current report
05.1.202422:30EDGAR2Form 8-K - Current report
15.12.202322:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
11.12.202314:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
20.11.202314:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
16.11.202322:30EDGAR2Form 8-K - Current report
16.11.202314:00BWAlzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid..
13.11.202314:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
30.10.202321:30EDGAR2Form 8-K - Current report
30.10.202313:00BWAlzamend Neuro Announces Reverse Stock Split
23.10.202314:00BWAlzamend Neuro Submits IND Application for a Phase IIA..
02.10.202314:00BWAlzamend Neuro Receives FDA “Study May Proceed” Notification..
29.9.202322:30EDGAR2Form 8-K - Current report
27.9.202300:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22.9.202322:30EDGAR2Form 8-K - Current report
22.9.202314:00BWAlzamend Neuro Granted Extension by Nasdaq Panel to Regain..
13.9.202323:09EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.9.202323:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08.9.202323:00EDGAR2Form 8-K - Current report
01.9.202322:30EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
30.8.202314:00BWAlzamend Neuro Submits IND Application for Phase IIA..
24.8.202322:30EDGAR2Form DEF 14A - Other definitive proxy statements
16.8.202322:30EDGAR2Form 8-K - Current report
10.8.202322:30EDGAR2Form PRE 14A - Other preliminary proxy statements
07.8.202322:30EDGAR2Form 8-K - Current report
02.8.202322:31EDGAR2Form S-3 - Registration statement under Securities Act of..
27.7.202322:56EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22.6.202314:00BWAlzamend Neuro Announces Positive Phase IIA Clinical Trial..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock